Journal article
Association Between Low-Dose Rivaroxaban With or Without Aspirin and Ischemic Stroke Subtypes
Abstract
Importance: The COMPASS (Cardiovascular Outcomes for People Using Anticoagulation Strategies) randomized clinical trial was stopped early owing to the efficacy of low-dose rivaroxaban plus aspirin in preventing major cardiovascular events. The main reason for early trial termination was the effect of combination therapy on reducing ischemic strokes.
Objective: To analyze the association between low-dose rivaroxaban with or without aspirin and …
Authors
Perera KS; Ng KKH; Nayar S; Catanese L; Dyal L; Sharma M; Connolly SJ; Yusuf S; Bosch J; Eikelboom JW
Journal
JAMA Neurology, Vol. 77, No. 1, pp. 43–48
Publisher
American Medical Association (AMA)
Publication Date
January 1, 2020
DOI
10.1001/jamaneurol.2019.2984
ISSN
2168-6149